Nordic nations hold off on AstraZeneca jab as scientists probe safety concerns - FT中文網
登錄×
電子郵件/用戶名
密碼
記住我
請輸入郵箱和密碼進行綁定操作:
請輸入手機號碼,透過簡訊驗證(目前僅支援中國大陸地區的手機號):
請您閱讀我們的用戶註冊協議私隱權保護政策,點擊下方按鈕即視爲您接受。
新型冠狀病毒

Nordic nations hold off on AstraZeneca jab as scientists probe safety concerns

Caution after Oslo experts said link between blood disorders and vaccine highly likely
00:00

Norway has been one of the most successful countries in Europe in the fight against Covid-19, with only Iceland experiencing fewer deaths relative to the size of its population.

So when, after vaccinating 120,000 of its 5.3m people with the Oxford/AstraZeneca jab, Norway found six cases of severe blood clots in recipients that led to the death of four people, the number stood out.

“It is quite remarkable. For the young nurses, young doctors who have been vaccinated, it is not good news for them. The sentiment in Norway because of this is a little special,” Steinar Madsen, medical director at the Norwegian Medicines Agency, told the Financial Times.

Norway, Denmark and Sweden stand apart from the rest of Europe in their reluctance to restart use of the AstraZeneca jab after at least 16 countries last week temporarily suspended or limited its use over concerns about blood clots in a number of recipients. On Thursday, the European Medicines Agency declared the vaccine safe after its own probe found no link, and inoculation resumed in Germany, Italy, Spain and other countries, with France limiting its use to the over-55s.

The three Scandinavian nations say they will decide this week whether to restart their programmes. Late on Sunday evening, Norwegian authorities announced two further deaths — taking the total to four — of people suffering from an unusual set of symptoms: severe blood clots.

We have only had about 650 deaths so far . . . If we had been in a precarious situation like in the UK, the attitude of the Norwegian population would have been different

Steinar Madsen, medical director at the Norwegian Medicines Agency

The cases that sparked the concerns involve an unusual set of symptoms: severe blood clots alongside low levels of blood platelets and bleeding. Madsen said Norwegian experts had “never seen anything quite like this before”.

Norway dissented from the EMA decision because it wants the symptoms listed as a possible side effect. An investigation at Oslo University Hospital — where three of the Norwegians with the symptoms were hospitalised and one died — found it was highly likely there was a connection with the vaccine.

Since the safety concerns were first raised, the EMA and World Health Organization have continued to recommend use of the vaccine, saying the benefits outweighed the risks. On Thursday, the regulator said that out of 20m people who had received the AstraZeneca vaccine in Europe, including the UK, it had received and reviewed 25 reports of clots associated with low levels of blood platelets.

Madsen said Norway agreed with the EMA that for the population as a whole, the AstraZeneca vaccine had a “positive risk-benefit ratio”. However, he said, there were “some very severe cases” and the difficulty lay in balancing the various factors.

“We are in a very lucky position. We have only had about 650 deaths so far. We are in a totally different situation to the UK, Italy, Germany, France, Czechia. If we had been in a precarious situation like in the UK, the attitude of the Norwegian population would have been different,” he said.

Experts on immunity and infection say it is plausible that a heightened inflammatory response to vaccination could in extremely rare cases lead to serious and even fatal blood disorders, such as those observed in Europe. No direct link to the AstraZeneca vaccine has been proved and the mechanism of such a severe reaction is unknown.

Peter Openshaw, professor of experimental medicine at Imperial College London, pointed out that Covid-19 itself causes serious clotting disorders so it was possible that the virus’s spike protein, produced by the body after vaccination, might provoke a similar response in a small number of recipients. Alternatively, another component of the vaccine, such as the adenovirus vector used in the AstraZeneca jab, might induce an excessive immune reaction, he said. However, he stressed that such explanations were speculative.

Sten Vermund, the dean of Yale School of Public Health, also said the spike protein could explain any autoimmune reaction, noting both Norwegian and German scientists were independently postulating the same cause.

Stephan Lewandowsky, chair in cognitive psychology at the University of Bristol in the UK, argued that the small number of events found in smaller countries with a low number of vaccinations could be skewing the picture.

“Randomness is ‘lumpy’ and if you look at many smaller countries then you may find a clustering of cases in one or the other country by chance alone, even though there is no signal in the overall data,” he warned. “That’s why agencies like the EMA that look at all available data have the best information to make a decision about safety. ”

But there are examples with vaccines for other diseases where the risk-benefit ratio has led to a pause. In the US, Vermund said, the swine flu vaccine of 1976 was associated with a complex neurological condition called Guillain-Barre syndrome. “It was rare but serious and since the 1976 pandemic influenza did not manifest as feared, vaccination was stopped altogether,” he said. “The cost was not worth the benefit in that case. ”

A series of narcolepsy cases in Scandinavia after administration of the Pandemrix flu vaccine may have “sensitised” those countries to adverse vaccine events, said Peter English, a retired Public Health England consultant in communicable disease control.

“The number of cases of this rare condition was so small that it is not possible to be certain that the vaccine was the cause, but the current consensus seems to be that it likely was,” he said.

Madsen said another issue in Norway, a society known for high levels of mutual trust and openness, was that it was important for the authorities to be as transparent as possible. “The worst thing that could happen is that the population could think something is being hidden from them,” he added.

Penelope Ward, a professor of pharmaceutical medicine at King’s College London, said countries were free to make their own decisions and were “answerable to their populations” for them.

But, she warned: “That will include the continued risk of Covid infection and associated deaths, which both remain significantly more common in the Nordic region than the very rare risk of complex thrombotic or bleeding disorders reported following receipt of the vaccine. ”

版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。

如何理解伊隆•馬斯克

他對政府的攻擊在意識形態上並不連貫,但可以追溯到一種重視激進思想的工程思維方式。

誰來保衛歐洲?

夾在咄咄逼人的俄羅斯和脫離接觸的美國之間,非洲大陸的西方民主國家現在必須重新武裝,否則將付出代價。

點石成金:4000年來對黃金的誤解

貴金屬的價格最近創下歷史新高。但囤積真的是通往人類幸福的途徑嗎?

斯塔默在AI安全問題上緊隨川普立場

英國政府改變人工智慧監管戰略,希望與美國新政府建立更好的關係。

一週新聞小測:2025年2月15日

您對本週的全球重大新聞了解如何?來做個小測試吧!

美國企業界是否已對川普感到不滿?

對減稅和放鬆監管前景的樂觀情緒已經讓位於對貿易政策的焦慮。
設置字型大小×
最小
較小
默認
較大
最大
分享×